ThromboGenics Appoints Dr David Guyer to its Board of Directors
News Dec 23, 2013
ThromboGenics NV has announced the appointment of Dr David Guyer to its Board of Directors.
Dr Guyer M.D. is a long standing member of the US retina community and is currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation and also serves as Chairman of its board of directors.
Ophthotech Corporation is a public biopharmaceutical company focusing on discovering, developing and commercializing first-in-class therapies for the treatment of major ophthalmic diseases.
Ophthotech’s lead compound Fovista (previously known as E10030) is being evaluated in a Phase III trial for use in combination with anti-VEGF therapy for the treatment of patients with wet AMD. Ophthotech listed on Nasdaq in September 2013, raising $192 million in its IPO.
Dr. Guyer is also on the Boards of Allocure and Panoptica.
Dr.Guyer co-founded and served as CEO and a Director of Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings, and oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for the treatment of wet AMD. Eyetech was acquired by OSI Pharmaceuticals Inc for $935 million in 2005.
Staf Van Reet, the Chairman of ThromboGenics commenting on today’s announcement said, “I am delighted to welcome David to the Board. His decades of success in the ophthalmology space both in drug development and commercialization, particularly in the US, will be extremely valuable to ThromboGenics. We are continuing to maximize the potential of JETREA® for the treatment of symptomatic VMA and further develop our emerging portfolio of therapies for the treatment of diabetes-related retinal diseases.”
Dr Guyer has also had a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received his Bachelor of Science (B.S.) degree from Yale College summa cum laude and his medical degree (M.D.) from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.
Dr David Guyer, commenting on his appointment, said, “ThromboGenics has made significant progress in recent years, leading to the introduction of JETREA® in the US early in 2013. I am happy to be joining the board of this dynamic company as it works to create a new treatment paradigm for patients with early stage symptomatic VMA.”
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE